1yy8: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Image:1yy8.png|left|200px]]


<!--
==Crystal structure of the Fab fragment from the monoclonal antibody cetuximab/Erbitux/IMC-C225==
The line below this paragraph, containing "STRUCTURE_1yy8", creates the "Structure Box" on the page.
<StructureSection load='1yy8' size='340' side='right'caption='[[1yy8]], [[Resolution|resolution]] 2.00&Aring;' scene=''>
You may change the PDB parameter (which sets the PDB file loaded into the applet)
== Structural highlights ==
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
<table><tr><td colspan='2'>[[1yy8]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YY8 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1YY8 FirstGlance]. <br>
or leave the SCENE parameter empty for the default display.
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2&#8491;</td></tr>
-->
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1yy8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1yy8 OCA], [https://pdbe.org/1yy8 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1yy8 RCSB], [https://www.ebi.ac.uk/pdbsum/1yy8 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1yy8 ProSAT]</span></td></tr>
{{STRUCTURE_1yy8|  PDB=1yy8  |  SCENE=  }}
</table>
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
Check<jmol>
  <jmolCheckbox>
    <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/yy/1yy8_consurf.spt"</scriptWhenChecked>
    <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked>
    <text>to colour the structure by Evolutionary Conservation</text>
  </jmolCheckbox>
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1yy8 ConSurf].
<div style="clear:both"></div>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crystal structure of the antigen binding (Fab) fragment from cetuximab (Erbitux), an inhibitory anti-EGFR antibody, in complex with the soluble extracellular region of EGFR (sEGFR). The sEGFR is in the characteristic "autoinhibited" or "tethered" inactive configuration. Cetuximab interacts exclusively with domain III of sEGFR, partially occluding the ligand binding region on this domain and sterically preventing the receptor from adopting the extended conformation required for dimerization. We suggest that both these effects contribute to potent inhibition of EGFR activation.


===Crystal structure of the Fab fragment from the monoclonal antibody cetuximab/Erbitux/IMC-C225===
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.,Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM Cancer Cell. 2005 Apr;7(4):301-11. PMID:15837620<ref>PMID:15837620</ref>


 
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
<!--
</div>
The line below this paragraph, {{ABSTRACT_PUBMED_15837620}}, adds the Publication Abstract to the page
<div class="pdbe-citations 1yy8" style="background-color:#fffaf0;"></div>
(as it appears on PubMed at http://www.pubmed.gov), where 15837620 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_15837620}}
 
==About this Structure==
[[1yy8]] is a 4 chain structure of [[Monoclonal Antibody]] with sequence from [http://en.wikipedia.org/wiki/Mus_musculus,_homo_sapiens Mus musculus, homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YY8 OCA].


==See Also==
==See Also==
*[[Monoclonal Antibody]]
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]]
 
== References ==
==Reference==
<references/>
<ref group="xtra">PMID:15837620</ref><references group="xtra"/>
__TOC__
[[Category: Mus musculus, homo sapiens]]
</StructureSection>
[[Category: Ferguson, K M.]]
[[Category: Homo sapiens]]
[[Category: Jeffrey, P D.]]
[[Category: Large Structures]]
[[Category: Kussie, P.]]
[[Category: Mus musculus]]
[[Category: Li, S.]]
[[Category: Ferguson KM]]
[[Category: Schmitz, K R.]]
[[Category: Jeffrey PD]]
[[Category: Wiltzius, J J.W.]]
[[Category: Kussie P]]
[[Category: Antibody drug]]
[[Category: Li S]]
[[Category: Cancer]]
[[Category: Schmitz KR]]
[[Category: Fab fragment]]
[[Category: Wiltzius JJW]]
[[Category: Immune system]]

Latest revision as of 03:43, 21 November 2024

Crystal structure of the Fab fragment from the monoclonal antibody cetuximab/Erbitux/IMC-C225Crystal structure of the Fab fragment from the monoclonal antibody cetuximab/Erbitux/IMC-C225

Structural highlights

1yy8 is a 4 chain structure with sequence from Homo sapiens and Mus musculus. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 2Å
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crystal structure of the antigen binding (Fab) fragment from cetuximab (Erbitux), an inhibitory anti-EGFR antibody, in complex with the soluble extracellular region of EGFR (sEGFR). The sEGFR is in the characteristic "autoinhibited" or "tethered" inactive configuration. Cetuximab interacts exclusively with domain III of sEGFR, partially occluding the ligand binding region on this domain and sterically preventing the receptor from adopting the extended conformation required for dimerization. We suggest that both these effects contribute to potent inhibition of EGFR activation.

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.,Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM Cancer Cell. 2005 Apr;7(4):301-11. PMID:15837620[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005 Apr;7(4):301-11. PMID:15837620 doi:10.1016/j.ccr.2005.03.003

1yy8, resolution 2.00Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA